AVE (ASE:AVE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more AVE Charts. Click Here for more AVE Charts.](/p.php?pid=staticchart&s=AS%5EAVE&p=8&t=15)
Aventis and Intercell Sign Collaboration and License Agreement to Develop
Bacterial Vaccines
SWIFTWATER, Pa. and VIENNA, Austria, Feb. 17 /PRNewswire-FirstCall/ -- Aventis
S.A. and Intercell AG announced today the signing of a commercial license
agreement for the development of bacterial vaccines.
Under the terms of the agreement, Intercell will apply its Antigen
Identification Program (AIP) to identify relevant antigens, which will allow
Aventis Pasteur, the vaccines business of Aventis, to develop a next generation
protein-based vaccine.
Intercell will receive upfront payments, license fees, research and development
funding, milestone payments, and royalty payments on product sales. Aventis
Pasteur will receive exclusive worldwide rights to commercialize the vaccines
developed in the collaboration. Further financial details of the agreement were
not disclosed.
"This program will enable Aventis Pasteur to maintain its leadership position in
next generation vaccine development," commented Dr. Jeffrey Almond, senior
vice-president, global research and external R&D at Aventis Pasteur. "We expect
that the collaboration will allow Aventis Pasteur to significantly improve its
competitive position in the focus area of the collaboration."
"Aventis Pasteur is a leader and innovator in the vaccine field, and this
collaboration validates our capabilities in the development of novel and
improved vaccine products," stated Intercell's CEO Alexander von Gabain.
"Intercell's AIP is a novel, utterly comprehensive, rapid genomic technology for
identification of the most protective pathogen antigens that are discovered,
using human immune responses as the discovery engine."
About Aventis
Aventis is dedicated to treating and preventing disease by discovering and
developing innovative prescription drugs and human vaccines. In 2003, Aventis
generated sales of 16.79 billion euros, invested 2.86 billion euros in research
and development and employed approximately 69,000 people in its core business.
Aventis corporate headquarters are in Strasbourg, France. For more information,
please visit: http://www.aventis.com/.
Aventis Pasteur, the vaccines business of Aventis, produced 1.4 billion doses of
vaccine in 2003, making it possible to protect 500 million people across the
globe, which is about 1.4 million per day. The company offers the broadest range
of vaccines, providing protection against 20 bacterial and viral diseases.
For more information, please visit: http://www.aventispasteur.com/
About Intercell
Intercell is a biotechnology company focused on the development of vaccines
against infectious diseases. Intercell's lead products are, a therapeutic
hepatitis C vaccine, which has entered Phase II clinical testing in November
2002, and a vaccine against Japanese encephalitis that has successfully
undergone a phase II clinical study. A phase III clinical study is planned for
2004.
To date, Intercell AG has succeeded in raising venture capital totaling USD 100
million since becoming operational.
For further information on Intercell AG visit: http://www.intercell.com/
For Aventis
Statements in this news release containing projections or estimates of revenues,
income, earnings per share, capital expenditures, capital structure,or other
financial items; plans and objectives relating to future operations, products,
or services; future economic performance; or assumptions underlying or relating
to any such statements, are forward-looking statements subject to risks and
uncertainties. Actual results could differ materially depending on factors such
as the timing and effects of regulatory actions, the results of clinical trials,
the company's relative success developing and gaining market acceptance for new
products, the outcome of significant litigation, and the effectiveness of patent
protection. Additional information regarding risks and uncertainties is set
forth in the current Annual Report on Form 20-F of Aventis on file with the
Securities and Exchange Commission andin the current Annual Report - "Document
de Reference" - on file with the "Commission des Operations de Bourse" in
France, recently renamed "Autorite des marches financiers."
For Intercell
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements.
Aventis Pasteur contacts:
Len Lavenda
Aventis Pasteur US Media Relations
Tel.: +1 570 839 4446
Koren Wolman-Tardy
Aventis Pasteur Corporate Media Relations
Tel.: +33(0)4 37 37 72 73
Intercell AG contact:
Dr. Hannelore Gude Hohensinner
Head of Corporate Communication
Phone: +43-1-20620-116
Fax: +43-1-20620-800
mailto:
DATASOURCE: Aventis S.A.
CONTACT: Len Lavenda of Aventis Pasteur US Media Relations,
+1-570-839-4446, , or Koren Wolman-Tardy of Aventis
Pasteur Corporate Media Relations, +33-4-37-37-72-73,
; or Dr. Hannelore Gude Hohensinner, Head of
Corporate Communication of Intercell AG, +43-1-20620-116, fax,
+43-1-20620-800,
Web site: http://www.aventispasteur.com/
http://www.intercell.com/